Tirzepatide
- Generic Name
- Tirzepatide
- Brand Names
- Mounjaro
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 2023788-19-2
- Unique Ingredient Identifier
- OYN3CCI6QE
- Background
Tirzepatide is a novel dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist. Dual GIP/GLP-1 agonists gained increasing attention as new therapeutic agents for glycemic and weight control as they demonstrated better glucose control and weight loss compared to selective GLP-1 receptor agonists in preclini...
- Indication
Tirzepatide is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. In Europe, it may be used as monotherapy or in combination with other drugs used to treat diabetes.
...
- Associated Conditions
- Type 2 Diabetes Mellitus
- Associated Therapies
- -
Drugs like Ozempic now make up 5% of prescriptions in the US
Eli Lilly plans to test its GLP-1 drug, tirzepatide, for addiction treatment. The drug may counteract hedonistic pursuits, reducing opioid overdose risk. It also improved sleep apnea symptoms and reduced all-cause mortality, making it a candidate for life-extension research.
US FDA Takes Lilly's Mounjaro, Zepbound Off Shortage List But Gives Compounding Grace Period
US FDA removes Lilly's Mounjaro and Zepbound from shortage list, allowing compounding pharmacies 60 days and outsourcing facilities 90 days to transition patients to branded products.
EU reportedly reviewing link between Ozempic, rare eye disease
European drug regulators review research linking Novo Nordisk's Ozempic to rare eye disorder NAION, following studies suggesting increased risk in Type 2 diabetes patients. The European Medicines Agency will examine Danish studies, while Novo Nordisk maintains the benefit-risk profile of semaglutide remains unchanged.
FDA Says Shortage of GLP-1 Tirzepatide (Mounjaro, Zepbound) Is Over
The FDA reaffirmed the end of tirzepatide (Mounjaro, Zepbound) shortage, prompting compounding pharmacies to cease production within 60-90 days. Eli Lilly disputed claims of ongoing shortages, labeling compounded versions as untested knockoffs. Other GLP-1 drugs like Dulaglutide, Semaglutide, and Liraglutide remain in shortage.
Big Pharma's new DTC play: partnering with digital health providers
Eli Lilly partners with Ro to integrate LillyDirect, offering Zepbound single-dose vials at a discount, while Ro also sells compounded semaglutide. The partnership reflects Big Pharma adapting to DTC trends and battling compounded GLP-1s. The FDA is reviewing GLP-1 shortage rules, with compounded versions currently allowed. Ro maintains independent clinical decision-making, selling both branded and compounded products based on availability. Lilly and Pfizer face Senate scrutiny over DTC platform legality, with obesity drugs being a focus due to high demand and scalability.
Eli Lilly to launch weight-less, anti-diabetes drug in India next year
Eli Lilly plans to launch Tirzepatide (Mounjaro) in India by 2025 for treating type 2 diabetes and obesity, competing with Novo Nordisk's Ozempic. The company aims to reflect the drug's efficacy in its Indian pricing strategy. India, known as the diabetes capital, is a key market for Lilly, which is committed to addressing unmet needs with innovative products. Tirzepatide, a dual agonist, may offer greater weight loss benefits than semaglutide, but experts warn against misuse as a cosmetic product.
Novo's New Deal May End Wegovy Shortages. It Could Reshape the Pharma Industry Along ...
Novo Nordisk's acquisition of Catalent's manufacturing sites may resolve Wegovy supply issues but raises concerns for the pharmaceutical industry, as Novo Holdings now controls a major contract manufacturer.
Can weight loss drugs reduce healthcare costs?
Weight loss drugs like Ozempic, Wegovy, and Mounjaro, initially for diabetes, help users lose 15-20% of body weight by mimicking GLP-1 hormone. Despite promising reductions in obesity rates, studies show these drugs don't lower overall healthcare costs; in fact, medical expenses increase. The drugs don't address underlying appetite control issues, leading to weight regain post-use. They also cause muscle loss, potentially slowing metabolism.
3 Unstoppable Stocks to Buy Right Now
AstraZeneca, Eli Lilly, and Vertex Pharmaceuticals are considered unstoppable healthcare stocks due to strong business fundamentals, diverse portfolios, and innovative pipelines. AstraZeneca's acquisitions and growth potential, Eli Lilly's market-leading position and blockbuster drugs, and Vertex Pharmaceuticals' monopoly in cystic fibrosis treatments and innovative therapies make them top picks for long-term investment.
The biggest health breakthroughs of 2024 - from 'miracle' weight loss jabs to rising cancer cases
2024 saw breakthroughs in weight-loss jabs, HIV drugs, cancer vaccines, and dementia drugs, but also setbacks like rising cancer cases and childhood disease outbreaks.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath